.png){kind=icon}
.png){kind=icon}
Back
S
Stephanie Herold
department of hematology and medical oncology
5H-index
14Paper Count
124Citation Count
Published Papers 5
Publication Date
.png){kind=icon}
Trials in progress: CARMAN – study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.png)
BMC Cancer.png)
OAAI
BMC CancerIF3.4
OAAI.png){kind=icon}
Share.png){kind=icon}
SaveThe MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentBMC CancerOAAI
BMC CancerIF3.4
OAAIShareSave